Financing co-led by ARCH Venture Partners and GV (Google Ventures) to support continued advancement of PP405, a topical therapy designed to reactivate dormant hair follicle stem cells to restore hair growth Positive Phase 2a results in androgenetic alopecia support progression into Phase 3 trials in 2026 Cathy Friedman of GV has been appointed Chair of … Continue reading Pelage Pharmaceuticals Announces $120 Million Series B Financing to Advance Regenerative Medicine Treatments for Hair Loss